Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Briacell Therapeutics Corp. T.BCT

Alternate Symbol(s):  BCTX | BCTXW

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops immunotherapies to transform cancer care. The Company’s lead drug candidate, Bria-IMT, is a cell-based patented immunotherapy that stimulates a patient’s own cancer fighting cells to attack and destroy breast cancer tumors. The Company is advancing its targeted immunotherapy program by prioritizing a Phase II clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor. The Company is focused on conducting a Phase I/IIa clinical trial of Bria-IMT in a combination study with Incyte’s immune PD-1 inhibitor, retifanlimab, in advanced breast cancer. The Company is also developing Bria-OTS, an off-the-shelf personalized approach to whole cell cancer immunotherapy. The Bria-OTS immunotherapy is based on a patient’s HLA-type. Its pipeline also includes Bria-Pros, Bria-Lung, Bria-Mel and sCD80, which are in development to treat various cancers.


TSX:BCT - Post by User

Post by LondonInveston Apr 12, 2022 1:27pm
145 Views
Post# 34597579

1.1M Options Shares Bought 2 Days Left

1.1M Options Shares Bought 2 Days Left
Today, BCTX prior to its poster presentation this afternoon has had volatile trading moving around 20% with over 3 million shares traded. 

More interesting, there have been 11,000 contracts for the April 14, 2022 options expiration purchased today for $0.50/contract at a strike price of $12.50.  This represents 1.1 million shares betting stock will rise at least 30% to break even in next 2 days (rising from $10.05/share to $13 per share = strike of $12.50 + $0.50 option cost).  This is very aggressive and constant, growing options pressure all day.  I do not know anything except stock is very undervalued, but market or others seem to think a re-pricing is imminent - by this Friday.  

I am long shares and am watching all this unfold today.
<< Previous
Bullboard Posts
Next >>